Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366323 | 1.00 | ADORA3 (0.58) | ADORA3ADORA2AADORA2BADORA1TP53 | |
| SCHEMBL10602647 | 0.87 | ADORA3 (0.75) | ADORA3ADORA2AADORA2BADORA1TP53 | |
| SCHEMBL5364283 | 0.82 | DOT1L (0.59) | ADORA3ADORA1 | |
| SCHEMBL5364270 | 0.82 | DOT1L (0.59) | ADORA3ADORA1 | |
| SCHEMBL7732676 | 0.81 | SLC29A1 (0.55) | ADORA3ADORA2AADORA1TSHRSLC29A1 | |
| SCHEMBL5372080 | 0.80 | ADORA3 (0.64) | ADORA3ADORA2AADORA1LMNATSHR | |
| SCHEMBL5372073 | 0.80 | ADORA3 (0.64) | ADORA3ADORA2AADORA1LMNATSHR | |
| SCHEMBL7068486 | 0.79 | SLC29A1 (0.54) | ADORA3ADORA2AADORA1TSHRSLC29A1 | |
| SCHEMBL6660564 | 0.79 | ADORA3 (0.63) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL6660573 | 0.79 | ADORA3 (0.63) | ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027363-B1 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2003-06-04 | — | — | EP | claimed |
| EP-1027363-A2 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-16 | — | — | EP | claimed |
| WO-1999024450-A2 | ADENSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | claimed |
| US-7265111-B2 | Adenosine analogues and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-04 | — | — | US | disclosed |
| EP-1527083-A1 | NOVEL ADENOSINE ANALOGUES AND THEIR USE AS PHARMACEUTICAL AGENTS | Aventis Pharma Deutschland GmbH (DE) | 2005-05-04 | — | — | EP | disclosed |
| US-20040127434-A1 | Novel adenosine analogues and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| WO-2004003002-A1 | NOVEL ADENOSINE ANALOGUES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-08 | — | — | WO | disclosed |
| EP-1375508-A1 | N6-substituted adenosine analogues and their use as pharmaceutical agents | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-6407076-B1 | ANTIISCHEMIC, ANTILIPOLYTIC, ANTICONVULSANT AND HYPOTENSIVE AGENTS; CARDIOVASCULAR AND NERVOUS SYSTEM DISORDERS; ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION | 2002-06-18 | — | — | US | disclosed |
| EP-1027363-A2 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999024450-A2 | ADENSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127434-A1 | Novel adenosine analogues and their use as pharmaceutical agents | ADORA1, ADORA2A, ADORA2B | ADORA3 5/4885ADORA2A 2/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.